永顺生物
(839729)
| 流通市值：4.89亿 | | | 总市值：16.65亿 |
| 流通股本：8024.46万 | | | 总股本：2.73亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 66,495,478.87 | 314,282,861.48 | 252,920,068.67 | 152,714,720.89 |
| 营业收入 | 66,495,478.87 | 314,282,861.48 | 252,920,068.67 | 152,714,720.89 |
| 二、营业总成本 | 57,569,882.86 | 258,618,527.57 | 198,400,377.18 | 117,364,146.85 |
| 营业成本 | 28,621,261.44 | 129,407,847.65 | 102,529,892.44 | 57,859,923.42 |
| 税金及附加 | 507,383.21 | 2,238,473.81 | 1,754,782.5 | 1,111,521.26 |
| 销售费用 | 14,842,617.78 | 61,748,330.69 | 44,267,753.29 | 27,219,927.37 |
| 管理费用 | 9,239,835.06 | 43,141,693.47 | 33,513,093.97 | 21,104,022.97 |
| 研发费用 | 5,350,715.65 | 25,679,787.92 | 19,436,311.11 | 12,363,939.98 |
| 财务费用 | -991,930.28 | -3,597,605.97 | -3,101,456.13 | -2,295,188.15 |
| 其中:利息费用 | 156,978.15 | 1,908,682.18 | 1,633,183.86 | 1,100,212.13 |
| 其中:利息收入 | 1,123,276.96 | 5,620,329.1 | 4,731,143.91 | 3,333,854.38 |
| 加:公允价值变动收益 | 42,234.34 | 1,867,816.87 | 1,036,087.66 | 757,127.81 |
| 加:投资收益 | 1,608,775.65 | 5,274,819.48 | 3,771,847.38 | 2,346,527.77 |
| 资产处置收益 | - | 131,628.39 | 131,628.39 | - |
| 资产减值损失(新) | -2,878,158.57 | -2,841,005 | -1,869,258.32 | -2,133,640.76 |
| 信用减值损失(新) | 413,757.44 | -6,601,752.05 | -2,464,021.91 | -907,130.16 |
| 其他收益 | 1,248,740.12 | 7,607,195.11 | 6,301,913.15 | 5,496,790.08 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 9,360,944.99 | 61,103,036.71 | 61,427,887.84 | 40,910,248.78 |
| 加:营业外收入 | 75,948.14 | 5,044,731 | 5,038,401 | 5,031,156 |
| 减:营业外支出 | 16,391.83 | 866,920.4 | 869,280.7 | 543,627.89 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 9,420,501.3 | 65,280,847.31 | 65,597,008.14 | 45,397,776.89 |
| 减:所得税费用 | 1,045,989.79 | 7,222,103.06 | 7,859,774.77 | 5,607,131.34 |
| 六、净利润 | 8,374,511.51 | 58,058,744.25 | 57,737,233.37 | 39,790,645.55 |
| 持续经营净利润 | 8,374,511.51 | 58,058,744.25 | 57,737,233.37 | 39,790,645.55 |
| 归属于母公司股东的净利润 | 8,374,511.51 | 58,058,744.25 | 57,737,233.37 | 39,790,645.55 |
| (一)基本每股收益 | 0.03 | 0.21 | 0.21 | 0.15 |
| (二)稀释每股收益 | 0.03 | 0.21 | 0.21 | 0.15 |
| 九、综合收益总额 | 8,374,511.51 | 58,058,744.25 | 57,737,233.37 | 39,790,645.55 |
| 归属于母公司股东的综合收益总额 | 8,374,511.51 | 58,058,744.25 | 57,737,233.37 | 39,790,645.55 |
| 公告日期 | 2024-04-29 | 2024-04-29 | 2023-10-26 | 2023-08-08 |
| 审计意见(境内) | | 标准无保留意见 | | |